List of Tascenso Odt drug patents
Tascenso Odt is owned by Handa.
Tascenso Odt contains Fingolimod Lauryl Sulfate.
Tascenso Odt has a total of 3 drug patents out of which 0 drug patents have expired.
Tascenso Odt was authorised for market use on 23 December, 2021.
Tascenso Odt is available in tablet, orally disintegrating;oral dosage forms.
Tascenso Odt can be used as treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg.
The generics of Tascenso Odt are possible to be released after 19 January, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10555902 | HANDA | Stable fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
| US9925138 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
| US10925829 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient
Market Authorisation Date: 23 December, 2021
Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic